Organisation paid for research Program year 2025 Source: CMS Open Payments

Cerv

Neither a doctor nor a teaching hospital

Research payments

$66,346

6 payments

Through program year 2025, Cerv is reported as receiving $66,346 in research payments, across 6 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $32,960 2
2024 Research $14,000 1
2022 Research $13,904 2
2019 Research $5,482 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $66,346 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $19,960 1 payment
  2. A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) $14,000 1 payment
  3. NEUTRALIZE - Lokelma Metabolic Acidosis Study A double-blind randomized placebo-controlled parallel design multicenter phase IIIb study of Lokelmas effect on serum potassium and serum bicarbonate in patients with CKD hyperkalemia and metabolic acidosis of CKD $13,904 2 payments
  4. A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event $13,000 1 payment
  5. A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Roxadustat AZD9941 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis $5,482 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record